Artificial Intelligence/Machine Learning

Latest News


Latest Videos


More News

© Kaikoro - © Kaikoro - stock.adobe.com

AI agents operate only within workflows, but most organizations lack unified workflow management systems, making it difficult to identify where agents should be deployed or ensure they integrate effectively across connected business processes in clinical research.

AI churn—repeatedly restarting initiatives before scaling them—stems from organizational execution gaps rather than technology limitations, but agentic AI amplifies these gaps by requiring connected systems, trustworthy data, and disciplined governance from the start.

Clinical R&D modernization stalls through incremental optimization of individual workflows, but meaningful systemic change requires leaders to visualize structural relationships, understand hidden incentives, and identify leverage points that benefit the whole system rather than parts.

Research on clinical-trial design has described AI opportunities across cohort selection, patient stratification, endpoint assessment, and operational planning. Credit: Stock.Adobe.com/NicoElNino.

AI can improve recruitment only when it is embedded in protocol design, EHR-enabled matching, patient engagement, site workflow, and governance. The highest-value near-term use cases are human-in-the-loop decision-support applications with documented context of use, validation, privacy controls, and bias monitoring.

In this Q&A, Abraham Gutman, founder and CEO of AG Mednet, discusses why the clinical trial industry has mastered data capture but never built the execution architecture needed to act on it, how the right infrastructure changes the role of human experts, and why enthusiasm for agentic AI is outrunning what clinical trials can realistically support.